Martin S, Schernthaner G, Nerup J, Gries F A, Koivisto V A, Dupré J, Standl E, Hamet P, McArthur R, Tan M H
Diabetes Research Institute, University of Düsseldorf, FRG.
Diabetologia. 1991 Jun;34(6):429-34. doi: 10.1007/BF00403182.
In the Canadian/European randomized controlled study on cyclosporin A (CsA) in recent onset Type 1 (insulin-dependent) diabetes, treatment with the immunosuppressive drug had increased and maintained Beta-cell function and clinical remission during the first 12 months. Following discontinuation of the study drug and double-blinding after a mean of 13.8 months former CsA patients doubled the daily insulin dose within 6 months reaching the level of former placebo patients. The difference in Beta-cell function between the two groups was also lost. Metabolic control (HbA1c) was transiently worse in the former CsA group. Adverse effects of cyclosporin A on systolic blood pressure, haemoglobin levels, serum potassium and creatinine levels also remitted during that time. We conclude that treatment with cyclosporin A for a mean of 13.8 months had no long-lasting effect on the course of Type 1 diabetes persisting beyond drug discontinuation.
在加拿大/欧洲关于环孢素A（CsA）治疗新发1型（胰岛素依赖型）糖尿病的随机对照研究中，在最初12个月内，使用这种免疫抑制药物治疗可增强并维持β细胞功能及临床缓解。在平均13.8个月后停用研究药物并解除双盲后， former CsA患者在6个月内将每日胰岛素剂量翻倍，达到了 former 安慰剂患者的水平。两组之间的β细胞功能差异也消失了。 former CsA组的代谢控制（糖化血红蛋白）曾短暂变差。在此期间，环孢素A对收缩压、血红蛋白水平、血清钾和肌酐水平的不良影响也有所缓解。我们得出结论，平均13.8个月的环孢素A治疗对1型糖尿病病程没有持久影响，这种影响在停药后仍持续存在。 （注：原文中“former CsA patients”和“former placebo patients”中的“former”重复使用且表意不明，翻译时保留原文表述。）
